|
| Author | Number of patients | Method | Results |
|
| Beck et al. [10] (2009) | 26 | WB | Anti-PLA2R ABs:
(i) Positive when there was clinically significant disease activity in 70% of primary MN cases but in none of secondary MN cases (100% specificity)
(ii) Declined or disappeared in remission |
|
| Hofstra et al. [39] (2011) | 18 | WB | (i) 78% of MN patients were PLA2R ABs positive
(ii) PLA2R ABs levels correlated strongly with both clinical status and proteinuria |
|
| Beck et al. [40] (2011) | 35 | WB | (i) 71% of MN patients were PLA2R AB positive
(ii) Complete and partial remissions were more frequent in patients on rituximab who demonstrated decline or disappearance of PLA2R ABs (59 and 88% versus 0 and 33%)
(iii) Rituximab-induced changes in antibody levels preceded changes in proteinuria |
|
| Hoxha et al. [41] (2011) | 360 (100 primary MN; 17 secondary MN; 90 other GN; 153 controls) | IFA | (i) Positive PLA2R ABs had 52% sensitivity and 100% specificity to detect MN
(ii) PLA2R ABs levels may help the therapeutic decisions |
|
| Hofstra et al. [38] (2012) | 117 | IFA and ELISA | (i) 72%/74% of MN patients were anti-PLA2R ABs positive
(ii) Excellent concordance between IFA and ELISA
(iii) Correlation between baseline PLA2R ABs and proteinuria
(iv) Spontaneous remissions more frequent in patients with lower PLA2R AB titer (38% versus 4%) |
|
|
Svobodova et al. [44] (2013) | 84 | IFA | Only 22% of patients in remission were PLA2R ABs positive while PLA2R AG was found in 59% of the corresponding biopsies |
|
| Kanigicherla et al. [42] (2013) | 40/30 (90) | ELISA | High PLA2R ABs levels (170.8 mcg/mL) are linked with the following:
(i) Active disease
(ii) Higher risk of decline in renal function |
|
| Oh et al. [43] (2013) | 100/69 | WB | (i) 80% of nephrotic primary MN patients and 20% of patients with secondary MN were PLA2R ABs positive
(ii) PLA2R ABs titer at biopsy was related to MN activity but not to outcome |
|
| Bech Anneke et al. [45] (2014) | 48 | ELISA | (i) PLA2R ABs decreased after two months under immunosuppressive therapy (428 U/mL to 24 U/mL)
(ii) PLA2R ABs levels after 2 months of immunosuppressive therapy not at baseline predicted long-term outcome: 58% and 9% of negative and positive PLA2R ABs were in remission after 5 years |
|
| Hoxha et al. [46] (2014) | 133 | IFA and ELISA | (i) 82% of MN patients were PLA2R ABs positive
(ii) Patients experiencing remission had lower PLA2R ABs titers (23 versus 54 mcg/mL) and IgG4 at baseline
(iii) PLA2R ABs declined faster than proteinuria (81% versus 39% after 3 months)
(iv) PLA2R ABs titer at baseline was an independent risk factor for not achieving remission of proteinuria |
|
| Segarra-Medrano et al. [47] (2014) | 36 | | (i) PLA2R ABs titer was significantly greater in patients with remission and it preceded the clinical response
(ii) No association was observed between the antibody titer prior to treatment and the mean response time or the response at 12 months
(iii) Reduction in PLA2R ABs titre is significantly associated with the time until signs of remission |
|
